AngioDynamics (NASDAQ:ANGO) Updates FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of ($0.34)-($0.31) for the period, compared to the consensus earnings per share estimate of ($0.37). The company issued revenue guidance of $285-288 million, compared to the consensus revenue estimate of $284.89 million. AngioDynamics also updated its FY 2025 guidance to -0.340–0.310 EPS.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Performance

Shares of ANGO opened at $9.66 on Wednesday. The company has a 50 day moving average price of $10.30 and a 200-day moving average price of $8.84. AngioDynamics has a fifty-two week low of $5.47 and a fifty-two week high of $13.50. The stock has a market capitalization of $390.90 million, a PE ratio of -1.72 and a beta of 0.56.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same quarter in the prior year, the business earned ($0.05) earnings per share. AngioDynamics’s revenue was down .1% on a year-over-year basis. Equities research analysts forecast that AngioDynamics will post -0.37 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.